Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
3 Genomics Stocks to Unlock the Future of Medicine
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. 
Via InvestorPlace
Exposures Product Safety
Better Growth Stock: Archer Aviation or Prime Medicine?
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
3 Healthcare Stocks That Could Help Make You a Millionaire
These stocks each have reached an important turning point that could signal growth ahead. 
Via The Motley Fool
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years
These businesses are exciting and can also lead to outsized long-term returns. 
Via The Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 5 Years?
Does the recent approval make the stock a no-brainer buy? 
Via The Motley Fool
After This Landmark Win, Is CRISPR Therapeutics a Buy?
CRISPR Therapeutics stock already has advanced in the double digits this year. 
Via The Motley Fool
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
These stocks could bring investors more than just a lump of coal for Christmas. 
Via The Motley Fool
Exposures Coal
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
This biotech could have more winners on the way. 
Via The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy. 
Via InvestorPlace
Topics ETFs
Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock
Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Biotech Stock That Could Be the Next Amgen
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. 
Via The Motley Fool
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam
Via Benzinga
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
Exposures Product Safety
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
Intellia is approaching the finish line. 
Via The Motley Fool
Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails
On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices. 
Via Benzinga
Why CRISPR Stock Keeps Falling
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
Exposures Product Safety
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
The 3 Best Cathie Wood Stocks to Buy in December
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop. 
Via InvestorPlace
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.